CL2020002561A1 - Composiciones y métodos para el tratamiento de la distrofia macular - Google Patents

Composiciones y métodos para el tratamiento de la distrofia macular

Info

Publication number
CL2020002561A1
CL2020002561A1 CL2020002561A CL2020002561A CL2020002561A1 CL 2020002561 A1 CL2020002561 A1 CL 2020002561A1 CL 2020002561 A CL2020002561 A CL 2020002561A CL 2020002561 A CL2020002561 A CL 2020002561A CL 2020002561 A1 CL2020002561 A1 CL 2020002561A1
Authority
CL
Chile
Prior art keywords
macular dystrophy
compositions
treatment
methods
subject
Prior art date
Application number
CL2020002561A
Other languages
English (en)
Inventor
De La Camara Cristina Martinez-Fernandez
Robert Maclaren
Gregory S Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002561A1 publication Critical patent/CL2020002561A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Abstract

La divulgación proporciona una composición que comprende una secuencia de ácido nucleico que comprende (a) una secuencia que codifica un promotor de distrofia macular viteliforme 2 (VMD2), y (b) una secuencia que codifica una proteína bestrofina-1 (BEST1), así como el uso de estas composiciones para el tratamiento de la distrofia macular en un sujeto, que comprende la administración de la composición al ojo de un sujeto por una via subretiniana o supracoroidea.
CL2020002561A 2018-04-05 2020-10-02 Composiciones y métodos para el tratamiento de la distrofia macular CL2020002561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
CL2020002561A1 true CL2020002561A1 (es) 2021-04-23

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002561A CL2020002561A1 (es) 2018-04-05 2020-10-02 Composiciones y métodos para el tratamiento de la distrofia macular

Country Status (21)

Country Link
US (2) US20190307900A1 (es)
EP (1) EP3775233A1 (es)
JP (1) JP2021520232A (es)
KR (1) KR20210005040A (es)
CN (1) CN113056561A (es)
AU (1) AU2019247864A1 (es)
BR (1) BR112020020204A2 (es)
CA (1) CA3096088A1 (es)
CL (1) CL2020002561A1 (es)
CO (1) CO2020013690A2 (es)
EA (1) EA202092069A1 (es)
IL (1) IL277779A (es)
JO (1) JOP20200253A1 (es)
MA (1) MA52199A (es)
MX (1) MX2020010477A (es)
PE (1) PE20210918A1 (es)
PH (1) PH12020551641A1 (es)
RU (1) RU2020132890A (es)
SG (1) SG11202009759SA (es)
TW (1) TW202003052A (es)
WO (1) WO2019195727A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019363593A1 (en) * 2018-10-25 2021-04-29 Takeda Pharmaceutical Company Limited AAV triple-plasmid system
WO2020140007A1 (en) * 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
US20230112568A1 (en) * 2020-02-28 2023-04-13 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762864T3 (es) * 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282A1 (en) * 2013-11-20 2015-05-28 Fondazione Telethon Artificial dna-binding proteins and uses thereof
EP3077520A1 (en) * 2013-12-06 2016-10-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
AU2016227668B2 (en) * 2015-03-03 2019-06-27 Fondazione Telethon Multiple vector system and uses thereof
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY

Also Published As

Publication number Publication date
PH12020551641A1 (en) 2021-07-26
BR112020020204A2 (pt) 2021-01-19
US20190307900A1 (en) 2019-10-10
JP2021520232A (ja) 2021-08-19
TW202003052A (zh) 2020-01-16
CA3096088A1 (en) 2019-10-10
PE20210918A1 (es) 2021-05-19
CN113056561A (zh) 2021-06-29
CO2020013690A2 (es) 2021-04-19
SG11202009759SA (en) 2020-10-29
MX2020010477A (es) 2021-03-02
KR20210005040A (ko) 2021-01-13
EA202092069A1 (ru) 2021-03-12
IL277779A (en) 2020-11-30
US20230149566A1 (en) 2023-05-18
EP3775233A1 (en) 2021-02-17
AU2019247864A1 (en) 2020-10-22
MA52199A (fr) 2021-02-17
RU2020132890A (ru) 2022-05-06
JOP20200253A1 (ar) 2020-10-04
WO2019195727A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
CL2020002561A1 (es) Composiciones y métodos para el tratamiento de la distrofia macular
CY1121348T1 (el) Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
UY37997A (es) Agentes antivirales contra la hepatitis b
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY38476A (es) Inhibidores de arg1 y/o arg2
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
AU2017256910A1 (en) Optogenetic visual restoration using Chrimson
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
MX2019007788A (es) Composiciones y metodos para tratar condiciones de la piel mediante el uso de luz y clorhidrato de glucosamina.
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
CO2021003136A2 (es) Terapias de combinación
MX2019002321A (es) Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.
EA201892157A1 (ru) Фосфаплатиновые жидкие составы